- Home
- GMAB vs ONON Comparison
GMAB vs ONON Comparison
Compare GMAB & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ONON
- Stock Information
- Founded
- GMAB 1999
- ONON 2010
- Country
- GMAB Denmark
- ONON Switzerland
- Employees
- GMAB N/A
- ONON N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ONON Shoe Manufacturing
- Sector
- GMAB Health Care
- ONON Consumer Discretionary
- Exchange
- GMAB Nasdaq
- ONON Nasdaq
- Market Cap
- GMAB 17.4B
- ONON 14.8B
- IPO Year
- GMAB N/A
- ONON 2021
- Fundamental
- Price
- GMAB $32.12
- ONON $43.68
- Analyst Decision
- GMAB Strong Buy
- ONON Strong Buy
- Analyst Count
- GMAB 7
- ONON 19
- Target Price
- GMAB $41.17
- ONON $64.53
- AVG Volume (30 Days)
- GMAB 2.2M
- ONON 5.4M
- Earning Date
- GMAB 11-05-2025
- ONON 11-11-2025
- Dividend Yield
- GMAB N/A
- ONON N/A
- EPS Growth
- GMAB 77.72
- ONON N/A
- EPS
- GMAB 21.62
- ONON 0.52
- Revenue
- GMAB $3,646,881,232.00
- ONON $3,417,915,703.00
- Revenue This Year
- GMAB $24.25
- ONON $30.48
- Revenue Next Year
- GMAB $16.29
- ONON $23.93
- P/E Ratio
- GMAB $1.51
- ONON $84.63
- Revenue Growth
- GMAB 32.97
- ONON 35.67
- 52 Week Low
- GMAB $17.24
- ONON $34.59
- 52 Week High
- GMAB $33.63
- ONON $64.05
- Technical
- Relative Strength Index (RSI)
- GMAB 72.36
- ONON 48.27
- Support Level
- GMAB $28.36
- ONON $41.41
- Resistance Level
- GMAB $33.63
- ONON $42.79
- Average True Range (ATR)
- GMAB 0.62
- ONON 1.32
- MACD
- GMAB 0.11
- ONON 0.09
- Stochastic Oscillator
- GMAB 72.68
- ONON 44.52
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ONON On Holding AG
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.